Table 1.

Summary statistics of LY3045697 plasma pharmacokinetic (PK) parameters after single and multiple-daily dosing in the fed state by dose group (geometric mean (coefficient of variation (CV)%)).

Variable	0.1 mg LY3045697 (n=6)	0.3 mg LY3045697 (n=6)	1 mg LY3045697 (n=6)	3 mg LY3045697 (n=6)	10 mg LY3045697 (n=6)	30 mg LY3045697 (n=6)	100 mg LY3045697 (n=6)	300 mg LY3045697 (n=6)
After single daily dose of LY3045697 in the fed state
Cmax (ng/ml)	0.32 (28)	1.10 (33)	1.96 (49)	9.95 (37)	27.9 (24)	83.7 (25)	458 (27)	951 (20)
tmax (h)a	0.75 (0.50–1.00)	0.50 (0.50–1.00)	1.00 (0.50–2.00)	0.50 (0.50–0.50)	0.75 (0.50–2.00)	1.00 (0.50–2.00)	0.50 (0.50–1.00)	0.50 (0.50–1.00)
AUC0–inf (h*ng/ml)	nrb	nrb	12.1 (51)c	49.1 (31)d	138 (19)	482 (32)	1726 (15)	6226 (19)
t1/2 (h)	nrb	nrb	9.11 (43)c	8.73 (32)d	9.99 (20)	9.57 (20)	9.62 (28)	10.8 (30)
After 8 once-daily doses of LY3045697 in the fed state
	(n=12)		(n=12)		(n=12)		(n=12)
Cmax (ng/ml)	0.368 (30)		3.45 (36)		37.4 (29)		371 (37)
tmax (h) a	0.95 (0.50–3.00)		0.95 (0.50–3.00)		0.95 (0.50–2.00)		0.95 (0.50–0.95)
AUC0–tau (h*ng/ml)	NC		19.2 (29)		195 (22)		1818 (28)
t1/2 (h)	e		e		9.84 (18)		10.8 (26)

AUC_0–inf : area under the plasma concentration-time curve from time 0 to infinity; AUC_0–tau: area under the plasma concentration-time curve during the dosing interval of 24 h; C_max: maximum observed plasma concentration; CI: confidence interval; h: hour; n: number of subjects exposed; NC: if no quantifiable observations were reported until 24 h post-dose than AUC_0–tau was not calculated; nr: not reported; t_1/2: terminal elimination half-life; t_max: time to attain C_max.

^aMedian (range); ^bhalf-life and other PK parameters that rely on the terminal phase elimination rate constant were not calculable due to inadequate quantifiable observation interval; ^cn=3; ^dn=5; ^enot reported due to inadequate quantifiable terminal phase.